Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia

Cancer Epidemiology

Volumn 34, Issue 3, 2010, Pages 303-308

  Leung, Wing ^a,b   Neale, Geoffrey ^a   Behm, Fred ^a   Iyengar, Rekha ^a   Finkelstein, David ^a   Kastan, Michael B ^a,b   Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Children; DNA damage; Immunity; Lymphoblastic leukemia; Second malignancy

Indexed keywords

CD16 ANTIGEN; CD19 ANTIBODY; CD45RA ANTIGEN; CD45RO ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CANCER SURVIVOR; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INNATE IMMUNITY; LEUKEMIA CELL; LONG TERM CARE; LOW ENERGY RADIATION; LYMPHOCYTE COUNT; MEMORY T LYMPHOCYTE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; RADIATION RESPONSE; REGULATORY T LYMPHOCYTE; SCHOOL CHILD; SECOND CANCER; SIBLING; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; THYMUS FUNCTION;

ADOLESCENT; ADULT; CHILD; DNA DAMAGE; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; LYMPHOPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS; T-LYMPHOCYTES; THYMUS GLAND; TIME; YOUNG ADULT;

EID: 77952241296     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.03.008     Document Type: Article

References (50)

1. Smith MA, Ries LA, Gurney JG, Ross JA. SEER Pediatric Monograph: Leukemia. http://seer.cancer.gov/publications/childhood/leukemia.pdf.
2. Pui C.H., and Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 339 (1998) 605-615
3. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 (2006) 166-178
4. Kirk J.A., Raghupathy P., Stevens M.M., Cowell C.T., Menser M.A., Bergin M., et al. Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukaemia. Lancet 1 (1987) 190-193
5. Quigley C., Cowell C., Jimenez M., Burger H., Kirk J., Bergin M., et al. Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. N Engl J Med 321 (1989) 143-151
6. Mulhern R.K., Fairclough D., and Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 9 (1991) 1348-1356
7. Haupt R., Fears T.R., Robison L.L., Mills J.L., Nicholson H.S., Zeltzer L.K., et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. JAMA 272 (1994) 1427-1432
8. Jankovic M., Brouwers P., Valsecchi M.G., Van Veldhuizen A., Huisman J., Kamphuis R., et al., ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. Lancet 344 (1994) 224-227
9. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., and Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 (1991) 808-815
10. Oeffinger K.C., Mertens A.C., Sklar C.A., Yasui Y., Fears T., Stovall M., et al., Childhood Cancer Survivor Study. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 21 (2003) 1359-1365
11. Pui C.H., Behm F.G., Raimondi S.C., Dodge R.K., George S.L., Rivera G.K., et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321 (1989) 136-142
12. Neglia J.P., Meadows A.T., Robison L.L., Kim T.H., Newton W.A., Ruymann F.B., et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325 (1991) 1330-1336
13. Pui C.H., Pei D., Sandlund J.T., Campana D., Ribeiro R.C., Razzouk B.I., Rubnitz J.E., et al. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 23 (2005) 7936-7941
14. Pui C.H., Cheng C., Leung W., Rai S.N., Rivera G.K., Sandlund J.T., et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349 (2003) 640-649
15. Relling M.V., Rubnitz J.E., Rivera G.K., Boyett J.M., Hancock M.L., Felix C.A., et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354 (1999) 34-39
16. Robison L.L., Arthur D.C., Ball D.W., Danzl T.J., and Nesbit M.E. Cytogenetic studies of long-term survivors of childhood acute lymphoblastic leukemia. Cancer Res 42 (1982) 4289-4292
17. Rubin C.M., Robison L.L., Nesbit Jr. M.E., and Arthur D.C. Cytogenetic studies of long-term survivors of childhood acute lymphoblastic leukemia: a follow-up report. Med Pediatr Oncol 14 (1986) 295-299
18. Koishi S., Kubota M., Sawada M., Hirota H., Hashimoto H., Lin Y.W., et al. Biomarkers in long survivors of pediatric acute lymphoblastic leukemia patients: late effects of cancer chemotherapy. Mutat Res 422 (1998) 213-222
19. Rice S.C., Vacek P., Homans A.H., Messier T., Rivers J., Kendall H., et al. Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia. Cancer Res 64 (2004) 4464-4471
20. Gasser S., and Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol 16 October (5) (2006) 344-347
21. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 (2004) 316-323
22. Borella L., Green A.A., and Webster R.G. Immunologic rebound after cessation of long-term chemotherapy in acute leukemia. Blood 40 (1972) 42-51
23. Haining W.N., Neuberg D.S., Keczkemethy H.L., Evans J.W., Rivoli S., Gelman R., et al. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood 106 (2005) 1749-1754
24. van Tilburg C.M., Sanders E.A., Rovers M.M., Wolfs T.F., and Bierings M.B. Loss of antibodies and response to (re-)vaccination in children after treatment for acute lymphocytic leukemia: a systematic review. Leukemia 20 (2006) 1717-1722
25. Leung W., Iyengar R., Triplett B., Turner V., Behm F.G., Holladay M.S., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174 (2005) 6540-6545
26. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., Niethammer D., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172 (2004) 644-650
27. Hazenberg M.D., Otto S.A., Cohen Stuart J.W., Verschuren M.C., Borleffs J.C., Boucher C.A., et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 6 (2000) 1036-1042
28. Wu C.J., Chillemi A., Alyea E.P., Orsini E., Neuberg D., Soiffer R.J., et al. Reconstitution of T cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transpantation is related to hematopoietic chimerism. Blood 95 (2000) 352-359
29. Kennedy G.C., Matsuzaki H., Dong S., Liu W.M., Huang J., Liu G., et al. Large-scale genotyping of complex DNA. Nat Biotechnol 21 (2003) 1233-1237
30. Matsuzaki H., Loi H., Dong S., Tsai Y.Y., Fang J., Law J., et al. Parallel Genotyping of Over 10,000 SNPs Using a One-Primer Assay on a High-Density Oligonucleotide Array. Genome Research 14 (2004) 414-425
31. Bignell G.R., Huang J., Greshock J., Watt S., Butler A., West S., et al. High-Resolution Analysis of DNA Copy Number Using Oligonucleotide Microarrays. Genome Research 14 (2004) 287-295
32. Liang K.Y., and Zegar S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
33. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57 (1995) 289-300
34. Imai K., Matsuyama S., Miyake S., Suga K., and Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356 (2000) 1795-1799
35. Cerwenka A., and Lanier L.L. Natural killer cells, viruses and cancer. Nat Rev Immunol 1 (2001) 41-49
36. Costello R.T., Sivori S., Marcenaro E., Lafage-Pochitaloff M., Mozziconacci M.J., Reviron D., et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99 (2002) 3661-3667
37. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375 (1995) 155-158
38. Girardi M., Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., et al. Regulation of cutaneous malignancy by gammadelta T cells. Science 294 (2001) 605-609
39. Born W.K., Reardon C.L., and O'Brien R.L. The function of gammadelta T cells in innate immunity. Curr Opin Immunol 18 (2006) 31-38
40. Favreau C., Worman H.J., Wozniak R.W., Frappier T., and Courvalin J.C. Cell cycle-dependent phosphorylation of nucleoporins and nuclear pore membrane protein Gp210. Biochemistry 35 (1996) 8035-8044
41. Someya A., Moss J., and Nagaoka I. Involvement of a guanine nucleotide-exchange protein, ARF-GEP100/BRAG2a, in the apoptotic cell death of monocytic phagocytes. J Leukoc Biol 80 (2006) 915-921
42. Morishige M., Hashimoto S., Ogawa E., Toda Y., Kotani H., Hirose M., et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat Cell Biol 10 (2008) 85-92
43. Hiroi T., Someya A., Thompson W., Moss J., and Vaughan M. GEP100/BRAG2: activator of ADP-ribosylation factor 6 for regulation of cell adhesion and actin cytoskeleton via E-cadherin and alpha-catenin. Proc Natl Acad Sci 103 (2006) 10672-10677
44. McLeod H.L., Krynetski E.Y., Relling M.V., and Evans W.E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14 (2000) 567-572
45. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005) 1186-1190
46. Xu Y. DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. Nat Rev Immunol 6 (2006) 261-270
47. Datta S.K. Role of natural effector cells in the prevention of radiation-induced leukemogenesis. Biomed Pharmacother 50 (1996) 125-131
48. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagita H., and Smyth M.J. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3 (2002) 83-90
49. Doria G., and Frasca D. Genes, immunity and senescence: looking for link. Immunol Rev 160 (1997) 159-170
50. Lombard D.B., Chua K.F., Mostoslavsky R., Franco S., Gostissa M., and Alt F.W. DNA repair, genome stability, and aging. Cell 120 (2005) 497-512